Exchange: NASDAQ·Updated 07:30 PM EST

SCYX News

News
all
press releases
SCYNEXIS Scores a Potential $214M Government Payday
BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.
24-7 Market News
SCYNEXIS Scores a Potential $214M Government Payday
BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.
24-7 Market News
More News
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Stocktwits
Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.
Stocktwits
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%read more...
Benzinga
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is atread more...
Benzinga
U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, SCYNEXIS, Box, and Zscaler after the closing bell.read more...
Benzinga
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million...
Nasdaq News: Markets
The biotech firm announced a deal to acquire a potential treatment for a kidney disease and secured $40 million through a private placement.
Stocktwits

Advertisement|Remove ads.